A case-controlled study of the oncologic safety of fat grafting

Katherine L Gale, Emad A Rakha, Graham Ball, Veronique K Tan, Stephen J McCulley, R Douglas Macmillan, Katherine L Gale, Emad A Rakha, Graham Ball, Veronique K Tan, Stephen J McCulley, R Douglas Macmillan

Abstract

Background: Currently, there is no clinical evidence of oncologic risk associated with fat grafting, although its safety has been questioned. The authors investigated the risk of relapse associated with fat grafting in women with a history of breast cancer.

Methods: Of 328 women with previously treated malignant breast disease who underwent fat grafting at the Nottingham Breast Institute, complete data were available for 211 (invasive carcinoma, n = 184; ductal carcinoma in situ, n = 27). Mean follow-up was 88 months after primary cancer surgery and 32 months after fat grafting. Control subjects were matched 2:1 for date of primary cancer operation (within 2 years), age (within 5 years), type of surgery, tumor histology, estrogen receptor status, and disease-free status by time equivalent to that of fat grafting. Final endpoints were tumor recurrence and death. Outcome results were compared with a systematic review of all patients undergoing fat grafting with adequate follow-up reported in the literature.

Results: No significant excess oncologic events were observed in patients who had fat grafting compared to controls with regard to local (0.95 percent versus 1.90 percent; p = 0.33), regional (0.95 percent versus 0 percent; p = 0.16), and distant recurrences (3.32 percent versus 2.61 percent; p = 0.65). A systematic review identified case series with a total of 1573 women who had fat grafting after primary oncologic breast surgery. The locoregional relapse rate for these patients was 2.92 percent (0.95 percent per year).

Conclusion: This study has found no evidence of increased oncologic risk associated with fat grafting in women previously treated for breast cancer.

Clinical question/level of evidence: Risk, II.

References

    1. Rigotti G, Marchi A, Galiè M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: A healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007;119:1409–1422
    1. Kling RE, Mehrara BJ, Pusic AL, et al. Trends in autologous fat grafting to the breast: A national survey of the American Society of Plastic Surgeons. Plast Reconstr Surg. 2013;132:35–46
    1. Petit JY, Lohsiriwat V, Clough KB, et al. The oncologic outcome and immediate surgical complications of lipofilling in breast cancer patients: A multicenter study—Milan-Paris-Lyon experience of 646 lipofilling procedures. Plast Reconstr Surg. 2011;128:341–346
    1. Largo RD, Tchang LA, Mele V, et al. Efficacy, safety and complications of autologous fat grafting to healthy breast tissue: A systematic review. J Plast Reconstr Aesthet Surg. 2014;67:437–448
    1. Ihrai T, Georgiou C, Machiavello JC, et al. Autologous fat grafting and breast cancer recurrences: Retrospective analysis of a series of 100 procedures in 64 patients. J Plast Surg Hand Surg. 2013;47:273–275
    1. Rigotti G, Marchi A, Stringhini P, et al. Determining the oncological risk of autologous lipoaspirate grafting for post-mastectomy breast reconstruction. Aesthetic Plast Surg. 2010;34:475–480
    1. Rietjens M, De Lorenzi F, Rossetto F, et al. Safety of fat grafting in secondary breast reconstruction after cancer. J Plast Reconstr Aesthet Surg. 2011;64:477–483
    1. Khouri RK, Eisenmann-Klein M, Cardoso E, et al. Brava and autologous fat transfer is a safe and effective breast augmentation alternative: Results of a 6-year, 81 patient, prospective multicentre study. Plast Reconstr Surg. 2012;129:1173–1187
    1. Petit JY, Botteri E, Lohsiriwat V, et al. Locoregional recurrence risk after lipofilling in breast cancer patients. Ann Oncol. 2012;23:582–588
    1. Petit JY, Rietjens M, Botteri E, et al. Evaluation of fat grafting safety in patients with intra epithelial neoplasia: A matched-cohort study. Ann Oncol. 2013;24:1479–1484
    1. Pérez-Cano R, Vranckx JJ, Lasso JM, et al. Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: The RESTORE-2 trial. Eur J Surg Oncol. 2012;38:382–389
    1. Brenelli F, Rietjens M, De Lorenzi F, et al. Oncological safety of autologous fat grafting after breast conservative treatment: A prospective evaluation. Breast J. 2014;20:159–165
    1. Perrot P, Rousseau J, Bouffaut AL, et al. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One. 2010;5:e10999
    1. Llanos AA, Dumitrescu RG, Marian C, et al. Adipokines in plasma and breast tissues: Associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev. 2012;21:1745–1755
    1. Chandler EM, Seo BR, Califano JP, et al. Implanted adipose progenitor cells as physicochemical regulators of breast cancer. Proc Natl Acad Sci USA. 2012;109:9786–9791
    1. Zhang Y, Daquinag A, Traktuev DO, et al. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009;69:5259–5266
    1. Martin-Padura I, Gregato G, Marighetti P, et al. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. Cancer Res. 2012;72:325–334
    1. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться